# Telmisartan

*Also known as: Micardis*

Angiotensin II receptor blocker; PPAR-γ activity may improve lipid profile on-cycle.

## Overview

Telmisartan (Micardis) is an angiotensin II receptor blocker used for hypertension, and used off-label in anabolic contexts for blood pressure management and its favorable metabolic profile. It blocks the angiotensin II type 1 receptor, lowering blood pressure and reducing afterload, while also showing partial PPAR-gamma agonist activity that may modestly improve insulin sensitivity and lipid markers. The compound has a roughly 23-hour half-life, reaches peak plasma within roughly 2 hours, and shows about 43% bioavailability, supporting once-daily dosing with effective 24-hour blood pressure control. Effects include blood pressure reduction and potential metabolic benefit, while risks are orthostatic hypotension when combined with other antihypertensives, and it should not be used in pregnancy given fetal harm. Harm reduction centers on confirming genuine hypertension rather than prophylactic use, on monitoring blood pressure and renal function, and on pairing it with lifestyle measures.

## Pharmacokinetics

- **Model tier:** advanced
- **Half-life:** 1.0 days (23.2999999992 hours)
- **Cmax:** 770.0625 ng/mL
- **Tmax:** 0.1 days
- **Bioavailability:** 43%

## Dosing

- **Default dose:** 40 mg
- **Typical range:** 20–80 mg
- **Units:** ng/mL

## Source

- **Label:** PubMed telmisartan PK
- **URL:** https://pubmed.ncbi.nlm.nih.gov/17009837/

---

**Canonical URL:** https://anabolicdex.com/compounds/telmisartan
**Plot:** https://anabolicdex.com/plot?compound=telmisartan